Novel Nitrile Peptidomimetics for Treating COVID-19
- ACS Med Chem Lett. 2022 Feb 3;13(3):330-331. doi: 10.1021/acsmedchemlett.2c00030.
Affiliations
- 1. Experimental Drug Development Centre, 10 Biopolis Road, Chromos #08-01, Singapore 138670.
PMID: 35291756
DOI: 10.1021/acsmedchemlett.2c00030
Abstract
COVID-19 is a highly infectious disease caused by the viral pathogen SARS-CoV-2, causing an estimated 5.4 million fatalities globally in 2 years since its emergence in December 2019. On December 22, 2021, the U.S. FDA granted Emergency Use Authorization for the oral viral main protease inhibitor, Nirmatrelvir, to treat patients with mild-to-moderate COVID-19. This patent review reveals the structure-activity relationship of key inhibitors described in the patent WO 2021/250648 A1.